Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27572327 | 0.86 | ALDH1A1 (0.63) | LMNASMN1; SMN2MAPTHTTCES2 | |
| SCHEMBL1515775 | 0.86 | MEN1 (0.61) | LMNASMN1; SMN2HTTCES2CES1 | |
| SCHEMBL25720199 | 0.86 | LMNA (0.62) | LMNASMN1; SMN2MAPTHTTNPC1 | |
| SCHEMBL6276599 | 0.85 | IDO1 (0.59) | SMN1; SMN2GAAALDH1A1KMT2ARAB9A | |
| SCHEMBL3894055 | 0.82 | ROCK1 (0.51) | LMNASMN1; SMN2MAPTHTTCES2 | |
| SCHEMBL2522956 | 0.81 | NPC1 (0.59) | LMNASMN1; SMN2MAPTHTTNPC1 | |
| SCHEMBL3073424 | 0.80 | NT5E (0.55) | LMNASMN1; SMN2GAAMAPTNPC1 | |
| SCHEMBL4748615 | 0.80 | RAB9A (0.56) | SMN1; SMN2MAPTCES2CES1NPC1 | |
| SCHEMBL3920349 | 0.80 | SMN1; SMN2 (0.44) | LMNASMN1; SMN2GAAMAPTHTT | |
| Hydrochloric Acid SCHEMBL11490902 | 0.79 | NPC1 (0.56) | LMNASMN1; SMN2GAAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524707-B2 | Bicyclic pyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-03 | — | — | US | disclosed |
| EP-2373664-B1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-10-20 | — | — | US | disclosed |
| EP-2373664-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010070060-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
| US-6962933-B1 | Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-0623126-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6436966-B1 | Adenosine A3 receptor antagonists | TAKEDA CHEMICAL IND., LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| EP-1027050-A2 | ADENOSINE A3 RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-08-16 | — | — | EP | disclosed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| WO-1999021555-A2 | ADENOSINE A3 RECEPTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-05-06 | — | — | WO | disclosed |
| US-5686455-A | Imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | LMNA 3321/4885SMN1; SMN2 4112/4885GAA 2036/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | LMNA 3773/4885SMN1; SMN2 4349/4885GAA 2982/4885 |
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K19, MAP4K3, MAP3K15 | LMNA 3683/4885SMN1; SMN2 4275/4885GAA 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.